Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Oxana Beskrovnaya sold 2,339 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the transaction, the insider now owns 140,375 shares of the company’s stock, valued at approximately $4,849,956.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Dyne Therapeutics Stock Up 6.0 %
Shares of DYN stock opened at $36.41 on Friday. The stock’s 50-day moving average price is $41.17 and its 200 day moving average price is $33.49. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.45. The stock has a market capitalization of $3.18 billion, a PE ratio of -9.17 and a beta of 1.07.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.02. Analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.
Institutional Trading of Dyne Therapeutics
Analysts Set New Price Targets
DYN has been the subject of a number of recent research reports. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Guggenheim lifted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Stifel Nicolaus lifted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. increased their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. Finally, Piper Sandler boosted their target price on Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.40.
Check Out Our Latest Stock Report on Dyne Therapeutics
About Dyne Therapeutics
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- Best Aerospace Stocks Investing
- 3 Dividend-Yielding Stocks Too Cheap to Pass Up
- CD Calculator: Certificate of Deposit Calculator
- Triple Witching: The Market’s Quarterly Rollercoaster
- Investing in Commodities: What Are They? How to Invest in Them
- 4 Stocks Set to Benefit from Recent Interest Rate Cuts
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.